• Aura Biosciences outlined a late-stage oncology pipeline led by EGFR inhibitor firmonertinib, with topline results from a global registrational Phase 3 first-line EGFR exon 20 insertion mutant NSCLC study expected in mid-2026.
• Firmonertinib holds FDA Breakthrough Therapy Designation and Orphan designation for first-line EGFR exon 20 insertion mutant NSCLC, with a separate global pivotal Phase 3 program ongoing in first-line EGFR PACC mutant NSCLC.
• Next-generation ADC portfolio includes ARR-217, a CDH17-targeting ADC in Phase 1, with Phase 1 dose-escalation completion targeted for 2H 2026.
• ARR-002, a NaPi2b x MUC16 tetravalent ADC, received US IND clearance, with Phase 1 initiation planned for 2H 2026.
• Cash and cash equivalents totaled USD 326.4 million as of March 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aura Biosciences Inc. published the original content used to generate this news brief on May 11, 2026, and is solely responsible for the information contained therein.